.svg)
.png)
.webp)
.svg)
.svg)
A3SMO® based first-in-class medicines targeting autoimmune diseases, fibrosis and obesity.
.webp)
.svg)
.webp)
LDN-0712 is being developed as a novel first-in-class, targeted A3SMO®-based Dual acting Anti fibro-inflammatory oral peptide mimic.
.png)
LDN-603 is being developed as a novel first-in-class, targeted A3SMO®-based Glp-1 agonist oral peptide mimic.
.svg)
.png)
.svg)
.svg)
